NCT05565092View on ClinicalTrials.gov

Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Sickle Cell Disease (SCD)
Interventions
DRUG

ALXN1820

ALXN1820 will be administered subcutaneously.

Trial Locations (2)

33023

Research Site, Hollywood

46260

Research Site, Indianapolis

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY